Long COVID Patient with Microclots Who Benefitted From Tollovid

Long COVID Patient with Microclots Who Benefitted From Tollovid

Symptoms Include: Loss of Taste and Smell, Fevers, Headaches, Body Aches, Fatigue, Cognitive Decline, Sleep Disturbance, Brain Fog, Elevated Heart Rate

A case study from a patient with Long Haulers who was recommended Tollovid by their physician Dr. Lee Morgentaler.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of a case study entitled “Consequences of Microclot Pathophysiology Underlying Long COVID Improved with Tollovid Supplementation”, overseen by Dr. Lee Morgentaler and Andrew A. Blumenthal, RN ADS of a patient who was experiencing symptoms of Post-Acute Sequelae of COVID (PASC, or “Long COVID”) for 27 months and had confirmed microclots diagnosis and InCellDx profiling who experienced resolution of clinical symptoms following supplementation with 3CL protease inhibitor immune support dietary supplement Tollovid™. The pre-publication can be viewed at:

https://www.researchgate.net/publication/363565069_Consequences_of_Microclot_Pathophysiology_Underlying_Long_COVID_Improved_with_Tollovid_Supplementation?_sg=NZwB29-FcunDkdZu7kf1Qebzrm_WJeCh_8BZXDXBAOk6hnFwzK6pVbDp_9uxNAvCNcJKGlw9sij07CA

ABSTRACT:
Alongside the COVID-19 outbreak, Long COVID proves to be a new emerging threat as millions of Americans suffer from lingering symptoms. While further research needs to be conducted regarding the underlying pathophysiology of Long COVID, many studies have revealed the presence of microclots in plasma samples from Long COVID patients. In the following case study, we document the journey of a Long COVID patient in whom microclots and hyperactivated platelets are observed. Following standard anti-coagulation therapy, supplementation with Tollovid, a botanical 3CL protease inhibitor, is initiated, which helps improve the patient’s overall trajectory of recovery.

About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel analyses, and Provista's proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at www.provistadx.com.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL protease–based diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid™ in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, while also developing the 3CL protease diagnostic TolloTest™.

For more information, please visit https://www.todosmedical.com/.

Regresar al blog